<DOC>
	<DOCNO>NCT00278993</DOCNO>
	<brief_summary>This multi-centre , phase II , open-label , two-stage design , single-arm study patient hormone-refractory prostate cancer ( HRPC ) advance ( rise PSA ) and/or metastatic disease prior anti-androgen therapy . The study explore efficacy E7389 enrollment patient two stratum : prior systemic chemotherapy disease ( except mitoxantrone estramustine ) , fail one previous chemotherapeutic regimen tubulin-binding agent docetaxel .</brief_summary>
	<brief_title>Evaluating E7389 Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified Prior Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion criterion : 1 . Males histologically proven adenocarcinoma prostate progress ( ie . minimum 3 consecutive rise Prostate Specific Antigen ( PSA ) ( last value ≥ 4 ng/mL ) take least 1 week apart prior study entry ) despite castration maintenance castratelevel testosterone ( define serum testosterone ≤ .50 ng/dL 1.7 nmol/L ) , progress nonhormonal chemotherapy . Note : Patients previously treat antiandrogen must disease progression document antiandrogen withdrawal . Those undergone orchiectomy must continue medical castration gonadotropinreleasing hormone analog . At least 4 week must elapse withdrawal antiandrogens ( 6 week case nilutamide bicalutamide four week case flutamide secondary hormonal therapy ) enrollment , avoid possibility confound result response due antiandrogen withdrawal . 2 . Patients must fulfill one follow two criterion stratify : No prior chemotherapy ( except mitoxantrone estramustine ) advance and/or metastatic disease define inclusion criterion # 1 . Failure one previous chemotherapeutic regimen tubulin bind agent docetaxel . 3 . Resolution chemotherapy radiationrelated toxicity less grade 2 severity , except neuropathy alopecia 4 . Age ≥ 18 year . 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . 6 . Life expectancy ≥ 3 month . 7 . Adequate renal function evidence serum creatinine ≤ 1.5 time upper limit normal ( ULN ) calculate creatinine clearance ≥ 40 mL/minute ( min ) per Cockcroft Gault formula . 8 . Adequate bone marrow function evidence absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L , hemoglobin ≥ 9.0 g/dL ( 5.5 mmol/L ) , platelet count ≥ 100 x 10^9/L . Adequate liver function evidence bilirubin ≤ 1.5 x ULN , alanine transaminase ( ALT ) , aspartate transaminase ( AST ) ≤ 3 x ULN ( case liver metastases ≤ 5 x ULN ) . 9 . Patients willing able complete VAS ( Visual Analog Scale ) . 10 . Patients willing able comply study protocol duration study . 11 . Written inform consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . Exclusion criterion : 1 . Patients receive chemotherapy , radiation , experimental therapy within 4 week start E7389 treatment 2 . Radiation therapy encompass ≥30 % marrow treatment radioactive strontium 3 . Patients require therapeutic anticoagulant therapy warfarin related compound ; ( mini dose warfarin related compound permit ) . 4 . Severe / uncontrolled intercurrent illness/infection . 5 . Significant cardiovascular impairment ( history congestive heart failure &gt; NYHA grade II , unstable angina myocardial infarction within past six month , serious cardiac arrhythmia ) 6 . Patients organ allograft . 7 . Patients know immunosuppression positive HIV status . 8 . Patients prior malignancy , nonmelanoma skin cancer , unless prior malignancy diagnose definitively treat ≥ 5 year previously subsequent evidence recurrence . 9 . Patients preexist neuropathy &gt; Grade 2 10 . Patients brain subdural metastasis eligible , except complete local therapy discontinue use corticosteroid indication least two week start treatment E7389 . 11 . Patients meningeal carcinomatosis . 12 . Patients hypersensitivity halichondrin B and/or halichondrin B chemical derivative . 13 . Patients participate prior E7389 clinical trial . 14 . Patients significant disease disorder , Investigator 's opinion , would exclude patient study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>metastatic disease</keyword>
</DOC>